Citation Tools
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies